Impurity profiling is a cornerstone of comprehensive pharmaceutical evaluation, characterizing the chemical structure, origin, and concentration of unintended components within drug substances. It answers the critical question: "What exactly is in the sample alongside the active ingredient?" Reliable impurity data is essential for understanding degradation pathways, assessing synthetic processes, and ensuring product safety. BOC Sciences offers comprehensive impurity profiling services utilizing a wide array of advanced analytical techniques. We help clients isolate, identify, and quantify organic and inorganic impurities, providing the robust data needed to optimize API analysis and formulation development.
BOC Sciences delivers customized Impurity Profiling evaluations with rapid turnaround times, helping you make data-driven decisions in the drug discovery pipeline.
Our advanced LC platforms coupled with high-resolution mass spectrometers provide unparalleled sensitivity for detecting trace organic impurities. This integrated approach allows for rapid molecular weight determination and precise LC-MS testing.
For volatile and semi-volatile compounds, our GC-MS systems deliver exceptional separation and identification capabilities. We rely on comprehensive GC-MS testing to accurately quantify residual solvents and process-related volatiles.
We utilize state-of-the-art multidimensional NMR spectroscopy to determine the exact connectivity and stereochemistry of unknown molecules. Rigorous NMR testing is indispensable for the unambiguous structural assignment of complex impurities.
When sufficient quantities of an impurity are required for testing or synthesis verification, our scalable systems isolate pure fractions. We employ advanced preparative HPLC techniques to enrich trace components from bulk drug substances.
Integrating data from mass spectrometry, NMR, and infrared spectroscopy allows us to assemble a complete molecular profile. This multi-technique strategy guarantees confident structure characterization of even the most elusive degradation products.
We map the complete profile of your sample by correlating chromatographic peaks with definitive chemical structures. Our systematic approach to impurities identification and characterization streamlines downstream process optimization.
BOC Sciences adapts analytical designs to suit the unique properties of various chemical matrices, ensuring relevant and accurate impurity assessment.
Submit your compound details and structural matrix. We will design a bespoke analytical study to demonstrate the purity profile of your asset.
Our analytical scientists review your compound properties and synthetic route to recommend the most appropriate techniques for your specific matrix.
We design customized chromatographic and spectroscopic methods tailored to separate and detect target impurities with high resolution and sensitivity.
The sample is analyzed in our controlled facilities. We perform comprehensive screening, targeted isolation, and rigorous data collection.
Isolated compounds are subjected to structural analysis, and data is interpreted by our experts. A final report containing methods, spectra, and structural conclusions is delivered.
We assist research teams in analyzing novel compounds under limited funding by offering flexible analytical screening and structural elucidation that generate critical data for publications without the overhead of purchasing expensive instrumentation. Our support can cover unknown impurity identification, degradation product analysis, and preliminary structure confirmation for early research programs.
To help startups secure investor confidence, we provide fast-track impurity screening with rapid turnaround times, delivering robust analytical data packages that support critical development milestones and quick synthetic optimization decisions. Typical projects include process-related impurity profiling, residual solvent testing, and key byproduct identification to support early CMC planning.
We support pharmaceutical companies facing capacity constraints by delivering scalable impurity profiling studies; our team handles complex, multi-batch analyses with rigorous standards to ensure data readiness for project advancement. This may include degradation pathway studies, elemental impurity assessment, batch comparison, and targeted characterization of trace-level unknowns.
For virtual companies lacking internal analytical infrastructure, we act as a dedicated partner offering end-to-end management, overseeing the entire lifecycle from method development to final reporting so you can focus on strategy. Our analytical support may involve chiral impurity monitoring, impurity isolation, reference standard support, and customized testing plans aligned with outsourced development programs.
Partner with BOC Sciences to access a diverse range of high-resolution instruments and structural elucidation techniques. Our scientific depth and flexible study designs provide the clear, actionable chemical data you need to drive your drug development forward.
We maintain a vast laboratory equipped with high-resolution mass spectrometers, advanced NMRs, and diverse chromatography systems, allowing for immediate project initiation and precise chemical analysis.
For novel molecular entities, our team can develop and optimize tailored analytical methods, designed specifically for the unique physical and chemical properties of your therapeutic candidate.
We integrate diverse analytical technologies, including LC-MS, GC-MS, and spectroscopic techniques, to provide a holistic view of the chemical composition and impurity landscape.
Our experienced analytical directors provide consultative support throughout the project, ensuring flexible adaptation to complex matrices while maintaining high scientific standards and reproducibility.
Client Needs: A biotech client needed to identify a novel impurity appearing during the shelf-life testing of their primary solid dosage form. The goal was to establish the chemical structure and origin of the degradant.
Challenges: The impurity was present at less than 0.05%, making standard detection and isolation extremely difficult without interfering with the main active ingredient. Additionally, the client needed to differentiate between an excipient interaction and an intrinsic API breakdown pathway.
Solution: BOC Sciences employed high-resolution LC-MS to determine the exact mass, followed by targeted preparative chromatography to enrich the sample from the bulk matrix. Advanced 2D NMR techniques were then applied to the isolated fraction to confidently map the molecular connectivity.
Outcome: The structure was conclusively identified as a unique oxidative degradant triggered by trace peroxide impurities in the excipient. This actionable data allowed the client to immediately adjust their formulation strategy, preventing further project delays.
Client Needs: A pharmaceutical developer required the precise characterization of a recurring byproduct in their newly scaled-up synthetic route. They needed structural certainty to optimize the reaction conditions.
Challenges: The impurity co-eluted with the main product in standard HPLC methods, and its chemical structure was suspected to be highly similar to the parent molecule, making spectroscopic differentiation challenging.
Solution: We developed a customized, orthogonal analytical method using ultra-performance liquid chromatography. Once separated, tandem mass spectrometry (MS/MS) provided the fragmentation pattern needed to deduce the structural difference between the main product and the byproduct.
Outcome: The impurity was identified as an unreacted intermediate derivative. The client used this precise structural information to modify the reaction temperature and duration, successfully eliminating the byproduct in subsequent scale-up batches.
Client Needs: A client sought to evaluate the enantiomeric purity of a complex small molecule drug candidate and identify any trace chiral impurities generated during an asymmetric synthesis step.
Challenges: Distinguishing between structurally identical enantiomers required highly specialized stationary phases and sensitive detection methods to accurately quantify trace levels against an overwhelming concentration of the desired enantiomer.
Solution: BOC Sciences screened a comprehensive library of specialized chiral columns and optimized the mobile phase to achieve a robust baseline separation. We then validated the method to ensure high sensitivity and precise quantification accuracy.
Outcome: The analytical package accurately quantified the undesired enantiomer at trace levels. The comprehensive data highlighted the robust enantioselectivity of their synthesis, triggering the next phase of optimization and confident compound advancement.
Impurity profiling plays a critical role in identifying and characterizing known and unknown impurities in APIs and intermediates. It helps researchers understand reaction pathways, by-products, and degradation behaviors. By building a comprehensive impurity profile, teams can optimize synthetic routes, improve consistency, and reduce risks during scale-up, making it an essential component of early-stage drug development decision-making.
Identification of unknown impurities typically relies on a combination of high-resolution mass spectrometry, NMR, and advanced separation techniques. Structural hypotheses are generated through fragmentation analysis and database comparisons, followed by experimental confirmation. Experienced partners like BOC Sciences integrate multiple analytical platforms to efficiently resolve trace-level impurities in complex systems, enabling faster and more reliable structural elucidation.
By tracking impurity formation and transformation across different process steps, scientists can determine whether impurities originate from starting materials, reaction conditions, or storage. This insight allows for targeted adjustments in parameters or route selection to minimize impurity generation at the source. Such data-driven optimization significantly enhances process robustness and reproducibility in drug development workflows.
Improving sensitivity in complex molecules involves optimizing sample preparation, selecting highly selective separation methods, and using sensitive detectors such as LC-MS/MS. Method development strategy is equally important. BOC Sciences offers tailored analytical solutions based on molecular characteristics, enabling accurate detection and quantification of low-level impurities even in challenging matrices.
By comparing impurity profiles across different batches, scientists can assess process stability and consistency trends. Analysis focuses not only on individual impurities but also on overall profile patterns to detect subtle variations. This comprehensive perspective helps identify potential risks and supports continuous optimization strategies during development and scale-up, ensuring consistent product quality performance.
The impurity profiling study conducted by BOC Sciences was executed flawlessly. The mass spectra were clean, the interpretations were precise, and the report provided deep insights into our synthetic route. It gave us the confidence to proceed to the next milestone.
— Ms. Natalie, Director of Chemistry, Emerging Biotech
We were unsure which analytical technique would best resolve our complex mixture. The team at BOC Sciences provided excellent consultation, developing a customized method that perfectly separated our target compounds. Their scientific input added immense value.
— Mr. Benjamin, Senior Analytical Scientist, Pharmaceutical Company
Structural elucidation is often a bottleneck, but BOC Sciences delivered results ahead of schedule. Their regular updates on analytical progress allowed us to monitor the profiling trends in real-time. Highly recommended for fast-paced R&D.
— Dr. Olivia, Project Leader, Drug Discovery Institute
Beyond just basic mass determination, the full NMR structural analysis provided by BOC Sciences helped us confirm the exact stereochemistry of our byproduct. The integration of spectroscopic data was seamless and professionally presented.
— Ms. Victoria, VP of Process Chemistry, Pharma Startup
